Obiageri Ihuarulam Okeoma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Obiageri Ihuarulam Okeoma has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Uchechukwu Bethel Abioke
Department of Physiotherapy, Faculty of Basic Medical Sciences, University of Benin, Benin, Nigeria
3 shared publications - Jazuli Isyaku Bala
Department of Hematology and Transfusion Medicine, Faculty of Clinical Sciences, Bayero University Kano, Aminu Kano Teaching Hospital Kano (AKTH), Kano, Nigeria
2 shared publications - Adepeju Kafayat Olowookere
Department of Nanoscience, University of North Carolina at Greensboro, Greensboro, NC, USA
1 shared publication Adesuwa Benedicta Osunde.
Department of Microbiology, Oduduwa University Ipetumodu Ile- Ife, Osun State, Nigeria
1 shared publication- Adetunji Olawale Adediran
Department of Internal Medicine, Faculty of Clinical Science, University College Hospital, Ibadan, Oyo State , Nigeria
1 shared publication - Adeyinka Moyinoluwa Adejumobi
Department of Data, Artificial Intelligence and Modelling, University of Hull, Hull, UK
1 shared publication
Latest Publications
- 15 July 2026
- Published by Australasia Publishing Group in International Journal of Evidence-Based Medicine
- Vol. 1 (3) , jebm010
Cost-Effectiveness of Fixed-Dose Combination Polypills for Secondary Cardiovascular Disease Prevention: A Systematic Review
Background: Cardiovascular disease remains a leading cause of global morbidity and mortality, and long-term secondary prevention is often limited by poor adherence, pill burden, treatment costs, and health system barriers. Fixed-dose combination polypills may simplify treatment by combining multiple cardiovascular medicines into a single formulation, thereby improving adherence and reducing recurrent cardiovascular events. Objective: This systematic review evaluated the cost-effectiveness of fixed-dose combination polypills compared with usual care, standard therapy, or separate monocomponents for secondary cardiovascular disease prevention across different healthcare and income settings. Methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Dimensions AI, ScienceDirect, and the Tufts Cost-Effectiveness Analysis Registry were searched for studies published between January 2015 and December 2025. Eligible studies included economic evaluations involving adults with established cardiovascular disease and reporting incremental cost-effectiveness ratios, cost per quality-adjusted life year, cost per disability-adjusted life year, cost savings, or related economic outcomes. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards checklist. Results: Fourteen records were included, comprising 13 full or partial economic evaluations and one Delphi consensus study with policy-relevant contextual interpretation. Most studies were conducted in high-income countries, particularly Spain, while evidence from low- and middle-income countries was limited. Fixed-dose combination polypills were generally reported as cost-effective or cost-saving, mainly driven by improved medication adherence, reduced pill burden, and prevention of recurrent cardiovascular events. Findings were also influenced by methodological factors such as analytic perspective and time horizon adopted across studies. Conclusion: Fixed-dose combination polypills may offer economic value for secondary cardiovascular disease prevention, but broader implementation should be guided by local cost-effectiveness, affordability, budget impact, and real-world evidence, especially in low- and middle-income countries.
- 15 July 2026
- Published by Australasia Publishing Group in International Journal of Evidence-Based Medicine
- Vol. 1 (3) , jebm010
Cost-Effectiveness of Fixed-Dose Combination Polypills for Secondary Cardiovascular Disease Prevention: A Systematic Review
Background: Cardiovascular disease remains a leading cause of global morbidity and mortality, and long-term secondary prevention is often limited by poor adherence, pill burden, treatment costs, and health system barriers. Fixed-dose combination polypills may simplify treatment by combining multiple cardiovascular medicines into a single formulation, thereby improving adherence and reducing recurrent cardiovascular events. Objective: This systematic review evaluated the cost-effectiveness of fixed-dose combination polypills compared with usual care, standard therapy, or separate monocomponents for secondary cardiovascular disease prevention across different healthcare and income settings. Methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Dimensions AI, ScienceDirect, and the Tufts Cost-Effectiveness Analysis Registry were searched for studies published between January 2015 and December 2025. Eligible studies included economic evaluations involving adults with established cardiovascular disease and reporting incremental cost-effectiveness ratios, cost per quality-adjusted life year, cost per disability-adjusted life year, cost savings, or related economic outcomes. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards checklist. Results: Fourteen records were included, comprising 13 full or partial economic evaluations and one Delphi consensus study with policy-relevant contextual interpretation. Most studies were conducted in high-income countries, particularly Spain, while evidence from low- and middle-income countries was limited. Fixed-dose combination polypills were generally reported as cost-effective or cost-saving, mainly driven by improved medication adherence, reduced pill burden, and prevention of recurrent cardiovascular events. Findings were also influenced by methodological factors such as analytic perspective and time horizon adopted across studies. Conclusion: Fixed-dose combination polypills may offer economic value for secondary cardiovascular disease prevention, but broader implementation should be guided by local cost-effectiveness, affordability, budget impact, and real-world evidence, especially in low- and middle-income countries.
- Open Access
- 29 May 2026
- Published by Ternopil State Medical University in International Journal of Medicine and Medical Research
- Vol. 12 (1) , 32-43
Comparative efficacy of regenerative therapies for β-cell preservation in diabetes mellitus: A meta-analysis
Diabetes mellitus, which is associated with progressive loss of pancreatic β-cells, leading to insulin deficiency and hyperglycaemia, is of global health concern. Regenerative therapies, including stem cell therapies, have potential to address β-cell depletion and improve diabetes outcomes. The objective of this review was to compare the efficacy of stem cell-based regenerative therapies for the management of patients with both type 1 and type 2 diabetes mellitus. In carrying out this review, PubMed, ClinicalTrials.gov, and Google Scholar were the primary databases consulted. The analysis of 9 studies, including 5 randomised controlled trials and 4 non-randomised studies, revealed modest improvements in C-peptide levels, particularly in patients with type 2 diabetes mellitus, with a mean difference of 0.09 (95% confidence interval: -0.03, 0.21; p-value = 0.13), suggesting some benefit for β-cell preservation. However, the therapies did not show improvements in glycated haemoglobin levels, an increase in glycated haemoglobin level was observed, with a mean difference of 0.71 (95% confidence interval: 0.27, 1.15; p-value = 0.002), indicating worsening of glucose control, particularly in patients with type 2 diabetes mellitus. Although stem cell therapies show promise for β-cell preservation, such interventions do not appear to improve glycaemic control. This research has significant implications for clinicians involved in diabetes care, particularly those exploring regenerative treatments for type 1 and type 2 diabetes mellitus, and it underscores the necessity for personalised therapeutic strategies that account for the distinct pathophysiological mechanisms in these types of diabetes Received: 21.01.2026 | Revised: 27.04.2026 | Accepted: 26.05.2026
- 29 May 2026
- Published by Ternopil State Medical University in International Journal of Medicine and Medical Research
- Vol. 12 (1) , 32-43
Open AccessComparative efficacy of regenerative therapies for β-cell preservation in diabetes mellitus: A meta-analysis
Diabetes mellitus, which is associated with progressive loss of pancreatic β-cells, leading to insulin deficiency and hyperglycaemia, is of global health concern. Regenerative therapies, including stem cell therapies, have potential to address β-cell depletion and improve diabetes outcomes. The objective of this review was to compare the efficacy of stem cell-based regenerative therapies for the management of patients with both type 1 and type 2 diabetes mellitus. In carrying out this review, PubMed, ClinicalTrials.gov, and Google Scholar were the primary databases consulted. The analysis of 9 studies, including 5 randomised controlled trials and 4 non-randomised studies, revealed modest improvements in C-peptide levels, particularly in patients with type 2 diabetes mellitus, with a mean difference of 0.09 (95% confidence interval: -0.03, 0.21; p-value = 0.13), suggesting some benefit for β-cell preservation. However, the therapies did not show improvements in glycated haemoglobin levels, an increase in glycated haemoglobin level was observed, with a mean difference of 0.71 (95% confidence interval: 0.27, 1.15; p-value = 0.002), indicating worsening of glucose control, particularly in patients with type 2 diabetes mellitus. Although stem cell therapies show promise for β-cell preservation, such interventions do not appear to improve glycaemic control. This research has significant implications for clinicians involved in diabetes care, particularly those exploring regenerative treatments for type 1 and type 2 diabetes mellitus, and it underscores the necessity for personalised therapeutic strategies that account for the distinct pathophysiological mechanisms in these types of diabetes Received: 21.01.2026 | Revised: 27.04.2026 | Accepted: 26.05.2026
- Open Access
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 434-453
Hormonal Dysregulation of Energy Expenditure and Adipose Tissue Metabolism in Non-Diabetic Adults with Obesity: Implications for Metabolic Inflammation and Weight-Loss Resistance
Background: Adults with obesity and normal glucose regulation are widely regarded as being at low metabolic risk. Endocrine research offers a weak basis for that view because it commonly recruits participants with and without type 2 diabetes into the same cohorts. Hormonal abnormalities are therefore attributed to diabetes when they may be demonstrable well before any diagnosis. Aim: To examine hormonal control of energy expenditure and adipose tissue metabolism in adults with obesity and no diabetes diagnosis, and to relate the alterations identified to metabolic inflammation and to weight-loss resistance. Methodology: Narrative review. MEDLINE and the Cochrane Library were searched to August 2026, supplemented by Google Scholar. Priority went to systematic reviews, meta-analyses, randomised trials, prospective cohorts and mechanistic human studies in adults with overweight or obesity and no diagnosis of diabetes. No formal risk-of-bias assessment was undertaken. Findings: Clamp measurement demonstrates impaired insulin sensitivity in adults meeting every published criterion for metabolic health, so normal fasting glucose reflects beta-cell compensation rather than insulin action. Leptin is abundant and ineffective, adiponectin falls as fat mass rises, and cortisol is amplified within adipose tissue while circulating concentrations remain unremarkable. Macrophages accumulate and release cytokines that interfere with the same signalling. Energy restriction adds a second layer. Ghrelin rises , peptide YY and cholecystokinin fall, leptin and insulin fall further, and none returns to baseline within a year. Resting metabolic rate also stays suppressed below what body composition predicts, even after substantial regain. Conclusion: Weight-loss resistance in normoglycaemic obesity has a measurable biological substrate. Incretin receptor agonists achieve substantial weight loss, but weight returns on withdrawal, suggesting that they oppose these regulatory changes without resetting them. Three gaps limit what can be concluded. Definitions are not standardised, African populations are barely represented, and almost no cohort has been followed from the normoglycaemic state.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 434-453
Open AccessHormonal Dysregulation of Energy Expenditure and Adipose Tissue Metabolism in Non-Diabetic Adults with Obesity: Implications for Metabolic Inflammation and Weight-Loss Resistance
Background: Adults with obesity and normal glucose regulation are widely regarded as being at low metabolic risk. Endocrine research offers a weak basis for that view because it commonly recruits participants with and without type 2 diabetes into the same cohorts. Hormonal abnormalities are therefore attributed to diabetes when they may be demonstrable well before any diagnosis. Aim: To examine hormonal control of energy expenditure and adipose tissue metabolism in adults with obesity and no diabetes diagnosis, and to relate the alterations identified to metabolic inflammation and to weight-loss resistance. Methodology: Narrative review. MEDLINE and the Cochrane Library were searched to August 2026, supplemented by Google Scholar. Priority went to systematic reviews, meta-analyses, randomised trials, prospective cohorts and mechanistic human studies in adults with overweight or obesity and no diagnosis of diabetes. No formal risk-of-bias assessment was undertaken. Findings: Clamp measurement demonstrates impaired insulin sensitivity in adults meeting every published criterion for metabolic health, so normal fasting glucose reflects beta-cell compensation rather than insulin action. Leptin is abundant and ineffective, adiponectin falls as fat mass rises, and cortisol is amplified within adipose tissue while circulating concentrations remain unremarkable. Macrophages accumulate and release cytokines that interfere with the same signalling. Energy restriction adds a second layer. Ghrelin rises , peptide YY and cholecystokinin fall, leptin and insulin fall further, and none returns to baseline within a year. Resting metabolic rate also stays suppressed below what body composition predicts, even after substantial regain. Conclusion: Weight-loss resistance in normoglycaemic obesity has a measurable biological substrate. Incretin receptor agonists achieve substantial weight loss, but weight returns on withdrawal, suggesting that they oppose these regulatory changes without resetting them. Three gaps limit what can be concluded. Definitions are not standardised, African populations are barely represented, and almost no cohort has been followed from the normoglycaemic state.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 152-164
Medical Nomenclature and Patient Understanding: Lessons from the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Transition
Background: Medical nomenclature can influence patients, clinicians, diagnostic accuracy, and health outcomes. On 12 May 2026, after a multi-year global consensus process, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS). The change reflected the recognition that the older term was scientifically imprecise and could contribute to delayed diagnosis, fragmented care, stigma, and limited patient understanding. Objectives: Using the PCOS-to-PMOS transition as a case study, this narrative review examines how an imprecise name may contribute to diagnostic delay, stigma, clinician confusion, and poorer outcomes. It synthesises evidence across five linked questions: how disease names shape patient understanding and health literacy; how they contribute to diagnostic delay and misdiagnosis; how they relate to stigma and psychosocial burden; how they influence clinician decision-making and care coordination; and what these effects imply for healthcare quality and patient safety. Methods: A narrative review of peer-reviewed literature, professional society publications, and grey literature was conducted using PubMed, Scopus, Web of Science, Google Scholar, and professional society websites. Search terms related to the phenomenon of interest, including “disease nomenclature,” “disease naming,” and “medical terminology,” were combined with terms describing its proposed effects, including “patient understanding,” “health literacy,” “diagnostic delay,” “stigma,” and “medical cognition,” and with condition-specific terms, including “PCOS,” “polycystic ovary syndrome,” and “PMOS.” Priority was given to studies addressing the effects of disease names on diagnosis, clinical outcomes, and health literacy. Findings: The evidence indicates that an imprecise name can weaken diagnostic accuracy through identifiable cognitive pathways. Cognitive load theory, conceptual anchoring, and semantic priming together explain how a name shapes patients’ and clinicians’ understanding. Historical reforms, from “hysteria” to specific diagnoses and from “Mongolism” to Down syndrome, show that more accurate naming has accompanied improved recognition and care. PCOS affects approximately one in eight women, or more than 170 million worldwide, yet up to 70% may remain undiagnosed or face diagnostic delays of several years. The PMOS revision illustrates how evidence-based terminology can be aligned with current scientific understanding. Conclusions: Medical terminology is not merely semantic; it shapes clinical reasoning, patient comprehension, and diagnostic and therapeutic pathways, with potential consequences for outcomes. The PCOS-to-PMOS transition shows that systematic, evidence-based nomenclature change is feasible and that disease names should reflect scientific understanding while supporting optimal care. Healthcare systems should treat nomenclature accuracy as a component of quality improvement and patient safety.
- 23 May 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (2) , 152-164
Medical Nomenclature and Patient Understanding: Lessons from the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Transition
Background: Medical nomenclature can influence patients, clinicians, diagnostic accuracy, and health outcomes. On 12 May 2026, after a multi-year global consensus process, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS). The change reflected the recognition that the older term was scientifically imprecise and could contribute to delayed diagnosis, fragmented care, stigma, and limited patient understanding. Objectives: Using the PCOS-to-PMOS transition as a case study, this narrative review examines how an imprecise name may contribute to diagnostic delay, stigma, clinician confusion, and poorer outcomes. It synthesises evidence across five linked questions: how disease names shape patient understanding and health literacy; how they contribute to diagnostic delay and misdiagnosis; how they relate to stigma and psychosocial burden; how they influence clinician decision-making and care coordination; and what these effects imply for healthcare quality and patient safety. Methods: A narrative review of peer-reviewed literature, professional society publications, and grey literature was conducted using PubMed, Scopus, Web of Science, Google Scholar, and professional society websites. Search terms related to the phenomenon of interest, including “disease nomenclature,” “disease naming,” and “medical terminology,” were combined with terms describing its proposed effects, including “patient understanding,” “health literacy,” “diagnostic delay,” “stigma,” and “medical cognition,” and with condition-specific terms, including “PCOS,” “polycystic ovary syndrome,” and “PMOS.” Priority was given to studies addressing the effects of disease names on diagnosis, clinical outcomes, and health literacy. Findings: The evidence indicates that an imprecise name can weaken diagnostic accuracy through identifiable cognitive pathways. Cognitive load theory, conceptual anchoring, and semantic priming together explain how a name shapes patients’ and clinicians’ understanding. Historical reforms, from “hysteria” to specific diagnoses and from “Mongolism” to Down syndrome, show that more accurate naming has accompanied improved recognition and care. PCOS affects approximately one in eight women, or more than 170 million worldwide, yet up to 70% may remain undiagnosed or face diagnostic delays of several years. The PMOS revision illustrates how evidence-based terminology can be aligned with current scientific understanding. Conclusions: Medical terminology is not merely semantic; it shapes clinical reasoning, patient comprehension, and diagnostic and therapeutic pathways, with potential consequences for outcomes. The PCOS-to-PMOS transition shows that systematic, evidence-based nomenclature change is feasible and that disease names should reflect scientific understanding while supporting optimal care. Healthcare systems should treat nomenclature accuracy as a component of quality improvement and patient safety.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 35-47
From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity
Background: Obesity is a chronic disease that is caused by dysregulation of the neurohormonal systems that regulate energy balance. With a weight loss of around 15% in randomized phase 3 trials, Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with greater weight-loss results than any other approved pharmacotherapy. The efficacy is due to the concurrent activation of hypothalamic appetite pathways, peripheral satiety hormones and enteric motility pathways. Methods: A narrative review of peer-reviewed literature was performed from 2015 to 2026. The following databases were searched: PubMed (MEDLINE), Scopus, and Google Scholar. The evidence was categorized in five mechanistic areas: the pharmacology of GLP-1 receptor, hypothalamic control of appetite and energy expenditure, peripheral satiety hormones, gut-brain axis signaling, and gastric motility. The strength of the evidence is indicated throughout, based on randomized trials, preclinical models, or observational studies. Results: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing. Conclusion: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing.
- 23 May 2026
- Published by IK Press in Journal of International Research in Medical and Pharmaceutical Sciences
- Vol. 21 (3) , 35-47
From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity
Background: Obesity is a chronic disease that is caused by dysregulation of the neurohormonal systems that regulate energy balance. With a weight loss of around 15% in randomized phase 3 trials, Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with greater weight-loss results than any other approved pharmacotherapy. The efficacy is due to the concurrent activation of hypothalamic appetite pathways, peripheral satiety hormones and enteric motility pathways. Methods: A narrative review of peer-reviewed literature was performed from 2015 to 2026. The following databases were searched: PubMed (MEDLINE), Scopus, and Google Scholar. The evidence was categorized in five mechanistic areas: the pharmacology of GLP-1 receptor, hypothalamic control of appetite and energy expenditure, peripheral satiety hormones, gut-brain axis signaling, and gastric motility. The strength of the evidence is indicated throughout, based on randomized trials, preclinical models, or observational studies. Results: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing. Conclusion: Semaglutide acts directly in the arcuate nucleus on GLP-1 receptor (GLP-1R) to inhibit orexigenic (for eating) NPY/AgRP neurons and enhance anorexigenic (appetite suppressant) POMC/CART signaling. This central effect is further enhanced by peripheral ghrelin suppression, increased postprandial insulin secretion, and increased vagal afferent satiety signals. Gastric emptying delay (via enteric GLP-1 receptor activation, vagal efferent cholinergic drive, and suppression of motilin) extends postprandial gastric distention, which strengthens the central satiety signal. This gastric effect is most significant when dosed initially for dose titration and then may decrease following chronic dosing.
- 8 May 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (4) , ehdi040
Endocrine-Disrupting Chemicals in Personal Care Products: Exposure Pathways and Health Effects
Endocrine-disrupting chemicals (EDCs) are exogenous substances that interfere with the normal functioning of the endocrine system, leading to adverse effects on human health, particularly in relation to reproductive, developmental, and metabolic processes. Recent research has increasingly identified personal care products (PCPs) as a major source of EDC exposure. These often contain chemicals such as parabens, phthalates, and triclosan, which retain endocrine activity even at low concentrations. This narrative review aimed to consolidate current research on the exposure pathways, health effects, and regulatory frameworks associated with EDCs in PCPs. A narrative review approach was adopted, focusing on studies published between 2021 and 2026. A comprehensive literature search was conducted in PubMed and ScienceDirect. The review found that EDCs are widely present in personal care products and dermal absorption, oral ingestion, and inhalation are the primary pathways through which EDCs enter the body. EDCs pose significant risks to human health, including reproductive dysfunction, developmental delays, metabolic disorders, and cancer risks with cumulative exposure exacerbating these risks. Regulatory frameworks vary globally, with many regions lagging in addressing the long-term impacts of EDC exposure. Ultimately, the findings emphasize the urgent need to address the public health implications of EDC exposure from PCPs, which contribute to chronic diseases across multiple systems. Effective policy recommendations include stricter regulations on EDCs in consumer products, better monitoring systems, and enhanced consumer awareness. These findings will be of significant value to public health officials, regulatory bodies, industry stakeholders, and health professionals who can influence and implement strategies for reducing EDC exposure to protect human health.
- 8 May 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (4) , ehdi040
Endocrine-Disrupting Chemicals in Personal Care Products: Exposure Pathways and Health Effects
Endocrine-disrupting chemicals (EDCs) are exogenous substances that interfere with the normal functioning of the endocrine system, leading to adverse effects on human health, particularly in relation to reproductive, developmental, and metabolic processes. Recent research has increasingly identified personal care products (PCPs) as a major source of EDC exposure. These often contain chemicals such as parabens, phthalates, and triclosan, which retain endocrine activity even at low concentrations. This narrative review aimed to consolidate current research on the exposure pathways, health effects, and regulatory frameworks associated with EDCs in PCPs. A narrative review approach was adopted, focusing on studies published between 2021 and 2026. A comprehensive literature search was conducted in PubMed and ScienceDirect. The review found that EDCs are widely present in personal care products and dermal absorption, oral ingestion, and inhalation are the primary pathways through which EDCs enter the body. EDCs pose significant risks to human health, including reproductive dysfunction, developmental delays, metabolic disorders, and cancer risks with cumulative exposure exacerbating these risks. Regulatory frameworks vary globally, with many regions lagging in addressing the long-term impacts of EDC exposure. Ultimately, the findings emphasize the urgent need to address the public health implications of EDC exposure from PCPs, which contribute to chronic diseases across multiple systems. Effective policy recommendations include stricter regulations on EDCs in consumer products, better monitoring systems, and enhanced consumer awareness. These findings will be of significant value to public health officials, regulatory bodies, industry stakeholders, and health professionals who can influence and implement strategies for reducing EDC exposure to protect human health.
- 9 April 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (3) , ehdi035
Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
Obesity is a chronic condition driven in part by disrupted appetite control and changes in gastrointestinal function, both of which contribute to excessive energy intake and progressive weight gain. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to produce meaningful weight loss in non-diabetic adults. Despite its growing clinical use, the physiological processes through which semaglutide influences appetite and gastric emptying have not been clearly brought together. This systematic review explored how semaglutide affects appetite regulation and gastric emptying, and how these effects relate to weight reduction. A systematic search was conducted in PubMed, Google Scholar, and Dimensions for studies published between 2021 and 2026, in line with PRISMA 2020 guidelines. Study screening, data extraction, and risk-of-bias assessment were carried out using Covidence by two independent reviewers, with a third reviewer resolving any disagreements. Four studies met the inclusion criteria, consisting of randomized controlled trials and one retrospective cohort study. Across randomized trials, semaglutide was consistently associated with greater improvements in appetite-related outcomes compared with placebo, including reductions in hunger scores and overall energy intake. Studies that assessed gastric physiology reported a notable delay in gastric emptying with semaglutide, particularly during the early stages of treatment. These physiological changes occurred alongside greater weight loss in semaglutide-treated participants compared with control groups. Longer-term findings suggested that appetite suppression was maintained over time and accompanied by clinically meaningful weight reduction, while observational data supported the effectiveness of semaglutide in routine clinical practice. Overall, the findings suggest that the weight-reducing effects of semaglutide in non-diabetic adults with obesity are closely tied to its ability to suppress appetite and slow gastric emptying. These mechanisms appear to play a central role in its therapeutic benefits and help explain the sustained weight loss observed with treatment.
- 9 April 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (3) , ehdi035
Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review
Obesity is a chronic condition driven in part by disrupted appetite control and changes in gastrointestinal function, both of which contribute to excessive energy intake and progressive weight gain. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to produce meaningful weight loss in non-diabetic adults. Despite its growing clinical use, the physiological processes through which semaglutide influences appetite and gastric emptying have not been clearly brought together. This systematic review explored how semaglutide affects appetite regulation and gastric emptying, and how these effects relate to weight reduction. A systematic search was conducted in PubMed, Google Scholar, and Dimensions for studies published between 2021 and 2026, in line with PRISMA 2020 guidelines. Study screening, data extraction, and risk-of-bias assessment were carried out using Covidence by two independent reviewers, with a third reviewer resolving any disagreements. Four studies met the inclusion criteria, consisting of randomized controlled trials and one retrospective cohort study. Across randomized trials, semaglutide was consistently associated with greater improvements in appetite-related outcomes compared with placebo, including reductions in hunger scores and overall energy intake. Studies that assessed gastric physiology reported a notable delay in gastric emptying with semaglutide, particularly during the early stages of treatment. These physiological changes occurred alongside greater weight loss in semaglutide-treated participants compared with control groups. Longer-term findings suggested that appetite suppression was maintained over time and accompanied by clinically meaningful weight reduction, while observational data supported the effectiveness of semaglutide in routine clinical practice. Overall, the findings suggest that the weight-reducing effects of semaglutide in non-diabetic adults with obesity are closely tied to its ability to suppress appetite and slow gastric emptying. These mechanisms appear to play a central role in its therapeutic benefits and help explain the sustained weight loss observed with treatment.
- Open Access
- 13 January 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (1) , aubm012
Gene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.
- 13 January 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (1) , aubm012
Open AccessGene Editing Therapies for Sickle Cell Disease and β-Thalassemia: A Systematic Review of Clinical Outcomes and Safety
Background: Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) remain major global health burdens. Ex vivo gene-editing therapies aim to achieve durable fetal hemoglobin (HbF) induction or direct mutation correction. Methods: We systematically reviewed clinical studies of CRISPR-Cas9 or base-editing therapies for SCD and TDT (MEDLINE, EMBASE, Web of Science, ClinicalTrials.gov, conference proceedings; 2010–03 December 2025). Eleven studies (>170 treated patients) reporting post-infusion outcomes were included. Results: All therapies produced robust, pancellular HbF (30–65%) and total hemoglobin in/near the normal range. In TDT (n > 100 evaluable), transfusion independence (≥12 months, Hb ≥9 g/dL) was achieved in 89–100% across platforms, sustained up to >4 years. In SCD (n > 60 evaluable), adjudicated vaso-occlusive crises were eliminated for ≥12 months in ≥97% of patients treated with exagamglogene autotemcel and 100% in smaller cohorts (EDIT-301, BEAM-101). No graft failures occurred. Serious adverse events and one death were attributable to busulfan conditioning, not editing. No therapy-related malignancies or confirmed harmful off-target edits have been reported, although follow-up remains limited (median ~18 months, longest >4 years). Conclusion: Current evidence from phase 1–3 trials demonstrates that ex vivo gene editing can achieve functional cure for many patients with TDT and severe SCD. Conditioning-related toxicity, limited long-term safety data, and delivery complexity remain critical barriers to broader implementation.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 129-141
Inflammatory Biomarkers as Predictors of Stroke Severity and Outcome: A Narrative Review
Background: Each year, nearly 12 million people suffer a stroke worldwide, resulting in over 7 million deaths, and approximately one in four adults is predicted to experience a stroke in their lifetime. Despite advances in acute stroke care and rehabilitation, stroke remains a leading cause of long-term disability. Inflammation plays a key role in stroke pathophysiology, influencing severity and recovery, and specific inflammatory biomarkers are increasingly recognized as potential indicators of patient outcomes. Objective: This narrative review examines the role of inflammatory biomarkers in relation to stroke severity and long-term outcomes. Methods: We conducted a narrative review of published studies on inflammatory biomarkers in stroke. Relevant articles were identified through searches of PubMed, Google Scholar, Dimensions, and Web of Science from January 2000 to December 2025. Studies were included based on relevance to stroke severity, prognosis, and biomarker assessment, encompassing both observational and experimental research. The narrative approach was used to qualitatively summarize findings, highlight methodological gaps, and propose directions for future research. Results: Elevated inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), CLEC4G, CKAP4, LY75, and ITGA11, have been associated with greater stroke severity, higher risk of complications, and poorer functional recovery. Composite indices and longitudinal biomarker profiling provide additional insight into the dynamics of post-stroke inflammation, supporting early risk stratification. Key gaps remain, including lack of standardization in biomarker measurement and potential confounding factors, which limit clinical translation. Conclusion: Inflammatory biomarkers show promise as indicators of stroke severity and prognosis. While they may help guide risk assessment and inform future targeted interventions, further validation is needed before routine clinical implementation.
- 3 January 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (1) , 129-141
Inflammatory Biomarkers as Predictors of Stroke Severity and Outcome: A Narrative Review
Background: Each year, nearly 12 million people suffer a stroke worldwide, resulting in over 7 million deaths, and approximately one in four adults is predicted to experience a stroke in their lifetime. Despite advances in acute stroke care and rehabilitation, stroke remains a leading cause of long-term disability. Inflammation plays a key role in stroke pathophysiology, influencing severity and recovery, and specific inflammatory biomarkers are increasingly recognized as potential indicators of patient outcomes. Objective: This narrative review examines the role of inflammatory biomarkers in relation to stroke severity and long-term outcomes. Methods: We conducted a narrative review of published studies on inflammatory biomarkers in stroke. Relevant articles were identified through searches of PubMed, Google Scholar, Dimensions, and Web of Science from January 2000 to December 2025. Studies were included based on relevance to stroke severity, prognosis, and biomarker assessment, encompassing both observational and experimental research. The narrative approach was used to qualitatively summarize findings, highlight methodological gaps, and propose directions for future research. Results: Elevated inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), CLEC4G, CKAP4, LY75, and ITGA11, have been associated with greater stroke severity, higher risk of complications, and poorer functional recovery. Composite indices and longitudinal biomarker profiling provide additional insight into the dynamics of post-stroke inflammation, supporting early risk stratification. Key gaps remain, including lack of standardization in biomarker measurement and potential confounding factors, which limit clinical translation. Conclusion: Inflammatory biomarkers show promise as indicators of stroke severity and prognosis. While they may help guide risk assessment and inform future targeted interventions, further validation is needed before routine clinical implementation.
- 2 January 2026
- Published by IK Press in Journal of Global Research in Education and Social Science
- Vol. 20 (1) , 153-168
An Empirical Study Exploring the Psychological Impacts of Social Media Usage among Adults
Background: Social media has become an integral part of daily life, influencing how adults communicate, seek information, and construct identities. However, there is growing concern about its psychological effects, especially regarding anxiety, depression, self-esteem, and sleep patterns. While substantial research has focused on adolescents, the impact of social media on adults' mental health remains under-explored. Objective: This study aims to address this gap by examining the psychological effects of social media use among adults, with particular attention to how different usage patterns—active engagement versus passive consumption—affect mental well-being. Methodology: A cross-sectional survey was conducted with 188 adult participants. Data were collected through an online questionnaire that assessed demographics, social media usage patterns, and psychological well-being (including anxiety, depression, self-esteem, and sleep disruption). Regression analysis was performed to determine the relationship between social media usage and mental health outcomes, controlling for demographic variables. Findings: The study found that while the amount of time spent on social media did not significantly affect anxiety, depression, self-esteem, or sleep disruption, social comparison was significantly associated with higher anxiety and depressive symptoms. FoMO also showed a trend toward increased anxiety, though not statistically significant. Additionally, passive social media consumption was linked to lower self-esteem, and both age and employment status were positively correlated with self-esteem. There were no significant relationships between social media use and sleep disruption. Conclusion: The study underscores the importance of understanding engagement patterns and internal psychological processes in the context of social media use. Future interventions should consider digital behavior patterns, promoting balanced engagement and mitigating the negative effects of comparison and FoMO. Further longitudinal studies are needed to establish causal relationships and explore long-term effects.
- 2 January 2026
- Published by IK Press in Journal of Global Research in Education and Social Science
- Vol. 20 (1) , 153-168
An Empirical Study Exploring the Psychological Impacts of Social Media Usage among Adults
Background: Social media has become an integral part of daily life, influencing how adults communicate, seek information, and construct identities. However, there is growing concern about its psychological effects, especially regarding anxiety, depression, self-esteem, and sleep patterns. While substantial research has focused on adolescents, the impact of social media on adults' mental health remains under-explored. Objective: This study aims to address this gap by examining the psychological effects of social media use among adults, with particular attention to how different usage patterns—active engagement versus passive consumption—affect mental well-being. Methodology: A cross-sectional survey was conducted with 188 adult participants. Data were collected through an online questionnaire that assessed demographics, social media usage patterns, and psychological well-being (including anxiety, depression, self-esteem, and sleep disruption). Regression analysis was performed to determine the relationship between social media usage and mental health outcomes, controlling for demographic variables. Findings: The study found that while the amount of time spent on social media did not significantly affect anxiety, depression, self-esteem, or sleep disruption, social comparison was significantly associated with higher anxiety and depressive symptoms. FoMO also showed a trend toward increased anxiety, though not statistically significant. Additionally, passive social media consumption was linked to lower self-esteem, and both age and employment status were positively correlated with self-esteem. There were no significant relationships between social media use and sleep disruption. Conclusion: The study underscores the importance of understanding engagement patterns and internal psychological processes in the context of social media use. Future interventions should consider digital behavior patterns, promoting balanced engagement and mitigating the negative effects of comparison and FoMO. Further longitudinal studies are needed to establish causal relationships and explore long-term effects.